SIC
VRTX icon

SJS Investment Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

SJS Investment Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3K Buy
59
+28
+90% +$12.4K ﹤0.01% 648
2026
Q1 		$13.8K Buy
31
+4
+15% +$1.86K ﹤0.01% 755
2025
Q4 		$12.2K Hold
27
– – ﹤0.01% 741
2025
Q3 		$10.6K Sell
27
-56
-67% -$23.4K ﹤0.01% 613
2025
Q2 		$37K Sell
83
-12
-13% -$5.53K 0.01% 210
2025
Q1 		$46.1K Buy
95
+30
+46% +$14K 0.01% 200
2024
Q4 		$26.2K Sell
65
-5
-7% -$2.32K ﹤0.01% 252
2024
Q3 		$32.6K Hold
70
– – 0.01% 233
2024
Q2 		$32.8K Hold
70
– – 0.01% 216
2024
Q1 		$29.3K Hold
70
– – 0.01% 240
2023
Q4 		$28.5K Sell
70
-84
-55% -$31K 0.01% 207
2023
Q3 		$53.6K Buy
154
+56
+57% +$19.6K 0.01% 153
2023
Q2 		$34.5K Buy
98
+2
+2% +$674 0.01% 178
2023
Q1 		$30.2K Sell
96
-6
-6% -$1.8K 0.01% 187
2022
Q4 		$29.5K Buy
102
+39
+62% +$11.9K 0.01% 193
2022
Q3 		$18K Buy
+63
New +$18.1K 0.01% 250
2022
Q1 		$3K Buy
+8
New +$1.9K ﹤0.01% 495

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SJS Investment Consulting's VRTX Position: Q2 2026 in Review

SJS Investment Consulting increased its Vertex Pharmaceuticals (VRTX) stake by 90% in Q2 2026, buying an estimated $12.4K and bringing the position to 59 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #648.

SJS Investment Consulting first reported a position in VRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $53.6K in Q3 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • SJS Investment Consulting held 59 shares of Vertex Pharmaceuticals worth $29.3K as of Q2 2026.
  • SJS Investment Consulting bought 28 Vertex Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
  • Vertex Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #648 holding.
  • SJS Investment Consulting first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • SJS Investment Consulting's Vertex Pharmaceuticals position peaked at $53.6K in Q3 2023.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.